<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976599</url>
  </required_header>
  <id_info>
    <org_study_id>A3921073</org_study_id>
    <nct_id>NCT00976599</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis</brief_title>
  <official_title>An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid
      arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28</measure>
    <time_frame>Day -7 (Baseline), Day 28</time_frame>
    <description>Synovial tissue biopsy were performed and assayed for mRNA gene expression by quantitative polymerized chain reaction (PCR) using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Interleukin-1beta (IL-1beta), IL-6, matrix metalloproteinase-3 (MMP3), cluster of differentiation 19 (CD19), cluster of differentiation 3 epsilon (CD3E), Janus kinase 1 (JAK1), JAK2, JAK3, signal transducers, activators of transcription (STAT1), interferon stimulated gene 15 (ISG15), C-X-C motif chemokine 10 (CXCL10), chemokine (C-C motif) ligand2 (CCL2), phospho-STAT1 (pSTAT1), pSTAT3, tumor necrosis factor alpha (TNFalpha), receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) presented as control gene normalized expression (relative expression) within synovial tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Protein Expression of Tumor Necrosis Factor Alpha (TNFalpha), Interleukin-6 (IL-6), Interleukin-17a (IL-17a) and Interleukin-10 (IL-10) at Day 28</measure>
    <time_frame>Baseline (Day -7), Day 28</time_frame>
    <description>Synovial tissue biopsy was to be performed and assayed for protein expression by quantitative PCR using standard curve method. Standard curve was to be generated by linear regression using log threshold cycle versus log (cell number). TNFalpha, IL-6, IL-17 and IL-10 data were to be presented as control normalized expression (relative expression) within synovial tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Percentage of Area Stained For CD3+ and CD68+ Surface Markers of Inflammatory Cells of the Synovial Tissue at Day 28</measure>
    <time_frame>Baseline (Day -7), Day 28</time_frame>
    <description>The intensity of CD3 and CD68 cell infiltration was expressed as the percentage area of the tissue section occupied by positively stained cells. Surface marker CD68 macrophages and CD3 thymus cells (T cells) in the inflammatory cells of synovial tissue were detected by immunohistochemical staining.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Baseline (Day-7)</measure>
    <time_frame>Baseline (Day -7)</time_frame>
    <description>Blood levels were utilized for expression analysis (mRNA) of following genes that reflect immune function: CD19, CD3 epsilon (CD3E), STAT1, STAT3, ISG15, CXCL10. mRNA gene expression in blood were assayed by quantitative PCR using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Data were presented as control gene normalized expression (relative expression) within blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Blood levels were utilized for expression analysis (mRNA) of following genes that reflect immune function: CD19, CD3E, STAT1, STAT3, ISG15, CXCL10. mRNA gene expression in blood were assayed by quantitative PCR using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Data were presented as control gene normalized expression (relative expression) within blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, active 70 kDa (p70) form of IL-12(IL-12p70), interferon gamma (IFNgamma) - induced protein 10 (IP-10), TNFalpha, granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein 1 alpha (MIP1a), monocyte chemotactic protein 1 (MCP1), soluble vascular endothelial growth factor (sVEGF), soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular adhesion molecule 1 (sICAM-1), granulocyte colony-stimulating factor (G-CSF) was measured by immunoassay and the levels were expresses as picogram per milliliter (pg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 hour post-dose on Day 1</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Cytokine Level at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Blood samples were collected for fluorescence-activated cell sorting [FACS] analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, Bone-marrow cells (B cells) and natural killer (NK) cells were analyzed using fluorescent-labeled antibodies against clusters of differentiation (CD) markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 Hour Post-dose on Day 1</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 Hours Post-dose on Day 1</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood T, B and NK Lymphocyte Counts and Possible Subsets at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific Enzyme-Linked Immunosorbent Assay [ELISA] method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 Hour Post-dose on Day 1</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 Hours Post-dose on Day 1</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 Hour Post-dose on Day 1</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 Hours Post-dose on Day 1</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH) Level at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 Hour Post-dose on Day 1</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 Hours Post-dose on Day 1</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin (OPG) Level at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegerin(OPG) Level at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Level of Matrix Metallopeptidase (MMP13)</measure>
    <time_frame>Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Level of Interleukin-34 (IL-34) and Interleukin-18 (IL-18)</measure>
    <time_frame>Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using meso scale discovery (MSD) single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific Electro ChemiLuminescent ImmunoAssay (ECLIA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 Hour Post-dose on Day 1</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 Hours Post-dose on Day 1</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 1</measure>
    <time_frame>1 Hour Post-dose on Day 1</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 1</measure>
    <time_frame>4 Hours Post-dose on Day 1</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 28</measure>
    <time_frame>1 Hour Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 28</measure>
    <time_frame>4 Hours Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 8 Hours Post-dose on Day 28</measure>
    <time_frame>8 Hours Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 1</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
    <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as nanogram per millimoles of creatinine (ng/mmol Cr).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 10</measure>
    <time_frame>Pre-dose on Day 10</time_frame>
    <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 28</measure>
    <time_frame>Pre-dose on Day 28</time_frame>
    <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at 24 Hours Post-dose on Day 28</measure>
    <time_frame>24 Hours Post-dose on Day 28</time_frame>
    <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 35 or Early Termination</measure>
    <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
    <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% Response</measure>
    <time_frame>Day 28, 35 or Early Termination</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Day 28, 35 or Early Termination</time_frame>
    <description>ACR50 response: &gt;=50% improvement in TJC; &gt;= 50% improvement in SJC; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Day 28, 35 or Early Termination</time_frame>
    <description>ACR70 response: &gt;=70% improvement in TJC; &gt;= 70% improvement in SJC; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</measure>
    <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP) (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Day 28 and 35</measure>
    <time_frame>Day 1 (Baseline), 28, 35 or Early Termination</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP (mg/mL). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) &lt;=3.2 and &lt;2.6</measure>
    <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP (mg/mL). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</measure>
    <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
    <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Day 28 and 35</measure>
    <time_frame>Day 1 (Baseline), 28, 35 or Early Termination</time_frame>
    <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR [mm/hour] and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) &lt;=3.2 and &lt;2.6</measure>
    <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
    <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR [mm/hour] and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CP-690,550 + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + methotrexate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550 + methotrexate</intervention_name>
    <description>CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week</description>
    <arm_group_label>CP-690,550 + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Methotrexate</intervention_name>
    <description>Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week</description>
    <arm_group_label>Placebo + methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a diagnosis of rheumatoid arthritis based on the American College of
             Rheumatology Association

          -  The subject has active disease at both Screening and Baseline, as defined:

               -  ≥4 joints tender or painful on motion, AND

               -  ≥4 joints swollen;

          -  The subject must have at least one knee, one elbow, one wrist or two
             metacarpophalangeal joints with active synovitis suitable for biopsy by the shaver
             technique

        Exclusion Criteria:

          -  No arthroscopy should have been performed in the past 3 months in the same joint that
             is to be biopsied in this study.

          -  No intra-articular steroids should have been injected in the joint to be biopsied in
             this study in the previous 3 months.

          -  Subjects with evidence of hematopoietic disorders or evidence of hemoglobin levels &lt;
             9.0 gm/dL or hematocrit &lt; 30 % at screening visit or within the 3 months prior to
             baseline synovial biopsy.

          -  An absolute white blood cell (WBC) count of &lt; 3.0 x 109/L (&lt;3000/mm3) or absolute
             neutrophil count of &lt;1.2 X 109/L (&lt;1200/mm3) at screening visit or within the 3 months
             prior to baseline synovial biopsy.

          -  Thrombocytopenia, as defined by a platelet count &lt;100 x 109/L (&lt; 100,000/mm3) at
             screening visit or within the 3 months prior to baseline synovial biopsy.

          -  Estimated GFR less than 40 ml/min based on Cockcroft Gault calculation .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sunnyvale</city>
        <state>Texas</state>
        <zip>75182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921073&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Mechanism%20Of%20Action%20Of%20CP-690%2C550%20In%20Patients%20With%20Rheumatoid%20Arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2013</results_first_posted>
  <disposition_first_submitted>November 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 7, 2012</disposition_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550</title>
          <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="9.2"/>
                    <measurement group_id="B2" value="53.1" spread="14.3"/>
                    <measurement group_id="B3" value="53.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28</title>
        <description>Synovial tissue biopsy were performed and assayed for mRNA gene expression by quantitative polymerized chain reaction (PCR) using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Interleukin-1beta (IL-1beta), IL-6, matrix metalloproteinase-3 (MMP3), cluster of differentiation 19 (CD19), cluster of differentiation 3 epsilon (CD3E), Janus kinase 1 (JAK1), JAK2, JAK3, signal transducers, activators of transcription (STAT1), interferon stimulated gene 15 (ISG15), C-X-C motif chemokine 10 (CXCL10), chemokine (C-C motif) ligand2 (CCL2), phospho-STAT1 (pSTAT1), pSTAT3, tumor necrosis factor alpha (TNFalpha), receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) presented as control gene normalized expression (relative expression) within synovial tissue.</description>
        <time_frame>Day -7 (Baseline), Day 28</time_frame>
        <population>Full analysis set (FAS) included all randomized participants who received at least 1 dose of the study medication. Analyses of tumor necrosis factor alpha(TNFα), receptor activator of nuclear factor kappa-B ligand(RANKL), osteoprotegerin(OPG) were not performed due to insufficient samples and lack of appropriate method to process/analyze samples.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28</title>
          <description>Synovial tissue biopsy were performed and assayed for mRNA gene expression by quantitative polymerized chain reaction (PCR) using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Interleukin-1beta (IL-1beta), IL-6, matrix metalloproteinase-3 (MMP3), cluster of differentiation 19 (CD19), cluster of differentiation 3 epsilon (CD3E), Janus kinase 1 (JAK1), JAK2, JAK3, signal transducers, activators of transcription (STAT1), interferon stimulated gene 15 (ISG15), C-X-C motif chemokine 10 (CXCL10), chemokine (C-C motif) ligand2 (CCL2), phospho-STAT1 (pSTAT1), pSTAT3, tumor necrosis factor alpha (TNFalpha), receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) presented as control gene normalized expression (relative expression) within synovial tissue.</description>
          <population>Full analysis set (FAS) included all randomized participants who received at least 1 dose of the study medication. Analyses of tumor necrosis factor alpha(TNFα), receptor activator of nuclear factor kappa-B ligand(RANKL), osteoprotegerin(OPG) were not performed due to insufficient samples and lack of appropriate method to process/analyze samples.</population>
          <units>relative expression unit (REU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: IL-1beta mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="0.77"/>
                    <measurement group_id="O2" value="-2.83" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: IL-6 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.72" spread="0.67"/>
                    <measurement group_id="O2" value="-3.96" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: MMP3 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.39"/>
                    <measurement group_id="O2" value="-2.52" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: CD19 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.98" spread="1.25"/>
                    <measurement group_id="O2" value="-3.46" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: CD3E mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="0.71"/>
                    <measurement group_id="O2" value="-1.75" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: JAK1 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.24"/>
                    <measurement group_id="O2" value="0.31" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: JAK2 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.26"/>
                    <measurement group_id="O2" value="0.15" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: JAK3 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.40"/>
                    <measurement group_id="O2" value="-0.88" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: STAT1 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.29"/>
                    <measurement group_id="O2" value="-0.46" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: ISG15 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="0.23"/>
                    <measurement group_id="O2" value="-1.33" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: CXCL10 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.85"/>
                    <measurement group_id="O2" value="-1.24" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: CCL2 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="0.29"/>
                    <measurement group_id="O2" value="-1.73" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: pSTAT1 protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.33"/>
                    <measurement group_id="O2" value="0.27" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: pSTAT3 protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.29"/>
                    <measurement group_id="O2" value="0.79" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: IL-1beta mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.88"/>
                    <measurement group_id="O2" value="0.09" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: IL-6 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.86"/>
                    <measurement group_id="O2" value="-0.08" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: MMP3 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.92"/>
                    <measurement group_id="O2" value="-0.03" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: CD19 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.85"/>
                    <measurement group_id="O2" value="-0.31" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: CD3E mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.53"/>
                    <measurement group_id="O2" value="-0.12" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: JAK1 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.36"/>
                    <measurement group_id="O2" value="-0.10" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: JAK2 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.40"/>
                    <measurement group_id="O2" value="-0.10" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: JAK3 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.35"/>
                    <measurement group_id="O2" value="-0.13" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: STAT1 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.46"/>
                    <measurement group_id="O2" value="0.01" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: ISG15 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.40"/>
                    <measurement group_id="O2" value="0.11" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: CXCL10 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.75"/>
                    <measurement group_id="O2" value="0.15" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: CCL2 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.30"/>
                    <measurement group_id="O2" value="-0.02" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: pSTAT1 protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.44"/>
                    <measurement group_id="O2" value="-0.10" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: pSTAT3 protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.42"/>
                    <measurement group_id="O2" value="-0.10" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Protein Expression of Tumor Necrosis Factor Alpha (TNFalpha), Interleukin-6 (IL-6), Interleukin-17a (IL-17a) and Interleukin-10 (IL-10) at Day 28</title>
        <description>Synovial tissue biopsy was to be performed and assayed for protein expression by quantitative PCR using standard curve method. Standard curve was to be generated by linear regression using log threshold cycle versus log (cell number). TNFalpha, IL-6, IL-17 and IL-10 data were to be presented as control normalized expression (relative expression) within synovial tissue.</description>
        <time_frame>Baseline (Day -7), Day 28</time_frame>
        <population>Analyses of TNFalpha, IL-6, IL-17 and IL-10 were not performed due to insufficient samples and lack of appropriate method to process/analyze the samples.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Protein Expression of Tumor Necrosis Factor Alpha (TNFalpha), Interleukin-6 (IL-6), Interleukin-17a (IL-17a) and Interleukin-10 (IL-10) at Day 28</title>
          <description>Synovial tissue biopsy was to be performed and assayed for protein expression by quantitative PCR using standard curve method. Standard curve was to be generated by linear regression using log threshold cycle versus log (cell number). TNFalpha, IL-6, IL-17 and IL-10 data were to be presented as control normalized expression (relative expression) within synovial tissue.</description>
          <population>Analyses of TNFalpha, IL-6, IL-17 and IL-10 were not performed due to insufficient samples and lack of appropriate method to process/analyze the samples.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Percentage of Area Stained For CD3+ and CD68+ Surface Markers of Inflammatory Cells of the Synovial Tissue at Day 28</title>
        <description>The intensity of CD3 and CD68 cell infiltration was expressed as the percentage area of the tissue section occupied by positively stained cells. Surface marker CD68 macrophages and CD3 thymus cells (T cells) in the inflammatory cells of synovial tissue were detected by immunohistochemical staining.</description>
        <time_frame>Baseline (Day -7), Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Area Stained For CD3+ and CD68+ Surface Markers of Inflammatory Cells of the Synovial Tissue at Day 28</title>
          <description>The intensity of CD3 and CD68 cell infiltration was expressed as the percentage area of the tissue section occupied by positively stained cells. Surface marker CD68 macrophages and CD3 thymus cells (T cells) in the inflammatory cells of synovial tissue were detected by immunohistochemical staining.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage area stained</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: CD3+ Cells (n=12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="6.12"/>
                    <measurement group_id="O2" value="7.92" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: CD68+ Cells (n=12, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.83" spread="20.59"/>
                    <measurement group_id="O2" value="32.85" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: CD3+ Cells (n=10, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="3.95"/>
                    <measurement group_id="O2" value="0.13" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28: CD68+ Cells (n=12, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="19.86"/>
                    <measurement group_id="O2" value="0.82" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Baseline (Day-7)</title>
        <description>Blood levels were utilized for expression analysis (mRNA) of following genes that reflect immune function: CD19, CD3 epsilon (CD3E), STAT1, STAT3, ISG15, CXCL10. mRNA gene expression in blood were assayed by quantitative PCR using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Data were presented as control gene normalized expression (relative expression) within blood.</description>
        <time_frame>Baseline (Day -7)</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Baseline (Day-7)</title>
          <description>Blood levels were utilized for expression analysis (mRNA) of following genes that reflect immune function: CD19, CD3 epsilon (CD3E), STAT1, STAT3, ISG15, CXCL10. mRNA gene expression in blood were assayed by quantitative PCR using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Data were presented as control gene normalized expression (relative expression) within blood.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>REU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD19 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.28"/>
                    <measurement group_id="O2" value="0.29" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3E mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.44"/>
                    <measurement group_id="O2" value="0.40" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAT1 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.25"/>
                    <measurement group_id="O2" value="0.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAT3 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.13"/>
                    <measurement group_id="O2" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISG15 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.45"/>
                    <measurement group_id="O2" value="-0.56" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="0.33"/>
                    <measurement group_id="O2" value="-1.65" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Day 28</title>
        <description>Blood levels were utilized for expression analysis (mRNA) of following genes that reflect immune function: CD19, CD3E, STAT1, STAT3, ISG15, CXCL10. mRNA gene expression in blood were assayed by quantitative PCR using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Data were presented as control gene normalized expression (relative expression) within blood.</description>
        <time_frame>Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Day 28</title>
          <description>Blood levels were utilized for expression analysis (mRNA) of following genes that reflect immune function: CD19, CD3E, STAT1, STAT3, ISG15, CXCL10. mRNA gene expression in blood were assayed by quantitative PCR using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Data were presented as control gene normalized expression (relative expression) within blood.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>REU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD19 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.24"/>
                    <measurement group_id="O2" value="0.30" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3E mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.34"/>
                    <measurement group_id="O2" value="0.40" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAT1 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.28"/>
                    <measurement group_id="O2" value="0.04" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAT3 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.13"/>
                    <measurement group_id="O2" value="0.59" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISG15 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.20"/>
                    <measurement group_id="O2" value="-0.48" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10 mRNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.22"/>
                    <measurement group_id="O2" value="-1.59" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at Pre-dose on Day 1</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, active 70 kDa (p70) form of IL-12(IL-12p70), interferon gamma (IFNgamma) - induced protein 10 (IP-10), TNFalpha, granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein 1 alpha (MIP1a), monocyte chemotactic protein 1 (MCP1), soluble vascular endothelial growth factor (sVEGF), soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular adhesion molecule 1 (sICAM-1), granulocyte colony-stimulating factor (G-CSF) was measured by immunoassay and the levels were expresses as picogram per milliliter (pg/mL).</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at Pre-dose on Day 1</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, active 70 kDa (p70) form of IL-12(IL-12p70), interferon gamma (IFNgamma) - induced protein 10 (IP-10), TNFalpha, granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein 1 alpha (MIP1a), monocyte chemotactic protein 1 (MCP1), soluble vascular endothelial growth factor (sVEGF), soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular adhesion molecule 1 (sICAM-1), granulocyte colony-stimulating factor (G-CSF) was measured by immunoassay and the levels were expresses as picogram per milliliter (pg/mL).</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.68"/>
                    <measurement group_id="O2" value="0.67" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.39"/>
                    <measurement group_id="O2" value="0.41" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.29"/>
                    <measurement group_id="O2" value="0.17" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.67"/>
                    <measurement group_id="O2" value="0.77" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.32"/>
                    <measurement group_id="O2" value="0.74" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.24"/>
                    <measurement group_id="O2" value="1.19" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.24"/>
                    <measurement group_id="O2" value="0.33" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.29"/>
                    <measurement group_id="O2" value="0.35" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.48"/>
                    <measurement group_id="O2" value="0.44" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.10"/>
                    <measurement group_id="O2" value="1.47" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="0.23"/>
                    <measurement group_id="O2" value="2.23" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.43"/>
                    <measurement group_id="O2" value="0.44" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.16"/>
                    <measurement group_id="O2" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.47"/>
                    <measurement group_id="O2" value="0.60" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.48"/>
                    <measurement group_id="O2" value="0.36" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="0.26"/>
                    <measurement group_id="O2" value="2.09" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.45"/>
                    <measurement group_id="O2" value="0.90" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.44"/>
                    <measurement group_id="O2" value="1.87" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="0.17"/>
                    <measurement group_id="O2" value="5.07" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="0.12"/>
                    <measurement group_id="O2" value="4.76" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at 1 Hour Post-dose on Day 1</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>1 hour post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at 1 Hour Post-dose on Day 1</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.68"/>
                    <measurement group_id="O2" value="0.73" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.42"/>
                    <measurement group_id="O2" value="0.40" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.28"/>
                    <measurement group_id="O2" value="0.15" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.52"/>
                    <measurement group_id="O2" value="0.78" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.36"/>
                    <measurement group_id="O2" value="0.72" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.31"/>
                    <measurement group_id="O2" value="1.15" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.22"/>
                    <measurement group_id="O2" value="0.31" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.31"/>
                    <measurement group_id="O2" value="0.34" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.46"/>
                    <measurement group_id="O2" value="0.42" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.16"/>
                    <measurement group_id="O2" value="1.45" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.25"/>
                    <measurement group_id="O2" value="2.22" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.46"/>
                    <measurement group_id="O2" value="0.44" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.07"/>
                    <measurement group_id="O2" value="0.10" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.47"/>
                    <measurement group_id="O2" value="0.62" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.49"/>
                    <measurement group_id="O2" value="0.39" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.26"/>
                    <measurement group_id="O2" value="2.03" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.47"/>
                    <measurement group_id="O2" value="0.89" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.42"/>
                    <measurement group_id="O2" value="1.87" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="0.15"/>
                    <measurement group_id="O2" value="5.06" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="0.13"/>
                    <measurement group_id="O2" value="4.76" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at 4 Hours Post-dose on Day 1</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>4 hours post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at 4 Hours Post-dose on Day 1</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.69"/>
                    <measurement group_id="O2" value="0.65" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.46"/>
                    <measurement group_id="O2" value="0.41" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.28"/>
                    <measurement group_id="O2" value="0.18" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.41"/>
                    <measurement group_id="O2" value="0.72" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.39"/>
                    <measurement group_id="O2" value="0.73" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.22"/>
                    <measurement group_id="O2" value="1.15" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.20"/>
                    <measurement group_id="O2" value="0.30" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.29"/>
                    <measurement group_id="O2" value="0.38" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.47"/>
                    <measurement group_id="O2" value="0.39" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.09"/>
                    <measurement group_id="O2" value="1.36" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="0.22"/>
                    <measurement group_id="O2" value="2.20" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.47"/>
                    <measurement group_id="O2" value="0.45" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.13"/>
                    <measurement group_id="O2" value="0.12" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.47"/>
                    <measurement group_id="O2" value="0.62" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.48"/>
                    <measurement group_id="O2" value="0.38" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.29"/>
                    <measurement group_id="O2" value="2.07" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.47"/>
                    <measurement group_id="O2" value="0.86" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.42"/>
                    <measurement group_id="O2" value="1.85" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="0.15"/>
                    <measurement group_id="O2" value="5.03" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="0.12"/>
                    <measurement group_id="O2" value="4.74" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at Pre-dose on Day 10</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at Pre-dose on Day 10</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.66"/>
                    <measurement group_id="O2" value="0.69" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.46"/>
                    <measurement group_id="O2" value="0.42" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.28"/>
                    <measurement group_id="O2" value="0.19" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.55"/>
                    <measurement group_id="O2" value="0.78" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.31"/>
                    <measurement group_id="O2" value="0.61" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.29"/>
                    <measurement group_id="O2" value="1.21" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.23"/>
                    <measurement group_id="O2" value="0.32" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.32"/>
                    <measurement group_id="O2" value="0.34" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.48"/>
                    <measurement group_id="O2" value="0.41" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.02"/>
                    <measurement group_id="O2" value="1.63" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.25"/>
                    <measurement group_id="O2" value="2.18" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.49"/>
                    <measurement group_id="O2" value="0.48" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.05"/>
                    <measurement group_id="O2" value="0.11" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.43"/>
                    <measurement group_id="O2" value="0.60" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.46"/>
                    <measurement group_id="O2" value="0.37" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.34"/>
                    <measurement group_id="O2" value="2.09" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.52"/>
                    <measurement group_id="O2" value="0.89" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.44"/>
                    <measurement group_id="O2" value="1.90" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="0.16"/>
                    <measurement group_id="O2" value="5.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="0.11"/>
                    <measurement group_id="O2" value="4.74" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at Pre-dose on Day 28</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at Pre-dose on Day 28</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.71"/>
                    <measurement group_id="O2" value="0.68" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.45"/>
                    <measurement group_id="O2" value="0.39" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.25"/>
                    <measurement group_id="O2" value="0.15" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.42"/>
                    <measurement group_id="O2" value="0.78" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.34"/>
                    <measurement group_id="O2" value="0.53" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.36"/>
                    <measurement group_id="O2" value="1.14" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.17"/>
                    <measurement group_id="O2" value="0.32" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.26"/>
                    <measurement group_id="O2" value="0.35" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.47"/>
                    <measurement group_id="O2" value="0.37" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="1.08"/>
                    <measurement group_id="O2" value="1.53" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.19"/>
                    <measurement group_id="O2" value="2.24" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.49"/>
                    <measurement group_id="O2" value="0.43" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.03"/>
                    <measurement group_id="O2" value="0.10" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.39"/>
                    <measurement group_id="O2" value="0.66" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.48"/>
                    <measurement group_id="O2" value="0.35" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.35"/>
                    <measurement group_id="O2" value="2.09" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.44"/>
                    <measurement group_id="O2" value="0.83" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.41"/>
                    <measurement group_id="O2" value="1.83" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" spread="0.14"/>
                    <measurement group_id="O2" value="5.01" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="0.09"/>
                    <measurement group_id="O2" value="4.70" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at 1 Hour Post-dose on Day 28</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at 1 Hour Post-dose on Day 28</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.68"/>
                    <measurement group_id="O2" value="0.69" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.41"/>
                    <measurement group_id="O2" value="0.39" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.25"/>
                    <measurement group_id="O2" value="0.15" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.52"/>
                    <measurement group_id="O2" value="0.77" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.38"/>
                    <measurement group_id="O2" value="0.61" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="0.23"/>
                    <measurement group_id="O2" value="1.12" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.16"/>
                    <measurement group_id="O2" value="0.33" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.28"/>
                    <measurement group_id="O2" value="0.36" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.45"/>
                    <measurement group_id="O2" value="0.36" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="1.06"/>
                    <measurement group_id="O2" value="1.52" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.21"/>
                    <measurement group_id="O2" value="2.23" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.46"/>
                    <measurement group_id="O2" value="0.43" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.06"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.39"/>
                    <measurement group_id="O2" value="0.66" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.47"/>
                    <measurement group_id="O2" value="0.36" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.30"/>
                    <measurement group_id="O2" value="2.06" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.45"/>
                    <measurement group_id="O2" value="0.83" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.38"/>
                    <measurement group_id="O2" value="1.81" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="0.15"/>
                    <measurement group_id="O2" value="5.04" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="0.10"/>
                    <measurement group_id="O2" value="4.73" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at 4 Hours Post-dose on Day 28</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at 4 Hours Post-dose on Day 28</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.69"/>
                    <measurement group_id="O2" value="0.75" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.32"/>
                    <measurement group_id="O2" value="0.33" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.27"/>
                    <measurement group_id="O2" value="0.14" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.30"/>
                    <measurement group_id="O2" value="0.69" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.45"/>
                    <measurement group_id="O2" value="0.56" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.21"/>
                    <measurement group_id="O2" value="1.07" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.13"/>
                    <measurement group_id="O2" value="0.28" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.27"/>
                    <measurement group_id="O2" value="0.31" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.44"/>
                    <measurement group_id="O2" value="0.34" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="1.05"/>
                    <measurement group_id="O2" value="1.68" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.21"/>
                    <measurement group_id="O2" value="2.13" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.42"/>
                    <measurement group_id="O2" value="0.38" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.07"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.43"/>
                    <measurement group_id="O2" value="0.72" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.47"/>
                    <measurement group_id="O2" value="0.38" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.23"/>
                    <measurement group_id="O2" value="1.99" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.48"/>
                    <measurement group_id="O2" value="0.80" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.36"/>
                    <measurement group_id="O2" value="1.84" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="0.15"/>
                    <measurement group_id="O2" value="5.00" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="0.09"/>
                    <measurement group_id="O2" value="4.71" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at 8 Hours Post-dose on Day 28</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at 8 Hours Post-dose on Day 28</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.68"/>
                    <measurement group_id="O2" value="0.63" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.35"/>
                    <measurement group_id="O2" value="0.34" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.27"/>
                    <measurement group_id="O2" value="0.14" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.39"/>
                    <measurement group_id="O2" value="0.79" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.40"/>
                    <measurement group_id="O2" value="0.66" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="0.21"/>
                    <measurement group_id="O2" value="1.17" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.11"/>
                    <measurement group_id="O2" value="0.29" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.28"/>
                    <measurement group_id="O2" value="0.33" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.42"/>
                    <measurement group_id="O2" value="0.29" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.04"/>
                    <measurement group_id="O2" value="1.30" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.22"/>
                    <measurement group_id="O2" value="2.14" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.43"/>
                    <measurement group_id="O2" value="0.35" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.00"/>
                    <measurement group_id="O2" value="0.12" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.37"/>
                    <measurement group_id="O2" value="0.83" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.45"/>
                    <measurement group_id="O2" value="0.38" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.31"/>
                    <measurement group_id="O2" value="2.02" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.45"/>
                    <measurement group_id="O2" value="0.71" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.36"/>
                    <measurement group_id="O2" value="1.82" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.16"/>
                    <measurement group_id="O2" value="5.05" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="0.09"/>
                    <measurement group_id="O2" value="4.74" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at 24 Hours Post-dose on Day 28</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at 24 Hours Post-dose on Day 28</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.66"/>
                    <measurement group_id="O2" value="0.66" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.41"/>
                    <measurement group_id="O2" value="0.38" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.27"/>
                    <measurement group_id="O2" value="0.15" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.42"/>
                    <measurement group_id="O2" value="0.99" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.35"/>
                    <measurement group_id="O2" value="0.64" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.32"/>
                    <measurement group_id="O2" value="1.18" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.17"/>
                    <measurement group_id="O2" value="0.30" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.25"/>
                    <measurement group_id="O2" value="0.37" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.44"/>
                    <measurement group_id="O2" value="0.32" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.98"/>
                    <measurement group_id="O2" value="1.64" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.31"/>
                    <measurement group_id="O2" value="2.27" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.47"/>
                    <measurement group_id="O2" value="0.42" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.19"/>
                    <measurement group_id="O2" value="0.10" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.39"/>
                    <measurement group_id="O2" value="0.71" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.46"/>
                    <measurement group_id="O2" value="0.31" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.24"/>
                    <measurement group_id="O2" value="2.10" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.49"/>
                    <measurement group_id="O2" value="0.88" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.41"/>
                    <measurement group_id="O2" value="1.84" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" spread="0.14"/>
                    <measurement group_id="O2" value="5.06" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="0.10"/>
                    <measurement group_id="O2" value="4.74" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Cytokine Level at Pre-dose on Day 35 or Early Termination</title>
        <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Cytokine Level at Pre-dose on Day 35 or Early Termination</title>
          <description>Blood samples were collected from all the participants and pro-inflammatory cytokine levels were measured. The levels of pro-inflammatory cytokine IL-1beta, IL-1alpha, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-7, IL-21, IL-12p70, IP-10, TNFalpha, IFNgamma, GM-CSF, MIP1a, MCP1, sVEGF, sVCAM-1, sICAM-1, G-CSF was measured by immunoassay and the levels were expresses as pg/mL.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.68"/>
                    <measurement group_id="O2" value="0.66" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.43"/>
                    <measurement group_id="O2" value="0.38" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.31"/>
                    <measurement group_id="O2" value="0.14" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.46"/>
                    <measurement group_id="O2" value="0.66" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.31"/>
                    <measurement group_id="O2" value="0.52" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.26"/>
                    <measurement group_id="O2" value="1.04" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.17"/>
                    <measurement group_id="O2" value="0.34" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.26"/>
                    <measurement group_id="O2" value="0.33" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.48"/>
                    <measurement group_id="O2" value="0.36" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.04"/>
                    <measurement group_id="O2" value="1.58" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="0.27"/>
                    <measurement group_id="O2" value="2.28" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.48"/>
                    <measurement group_id="O2" value="0.43" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.22"/>
                    <measurement group_id="O2" value="0.10" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.55"/>
                    <measurement group_id="O2" value="0.58" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.46"/>
                    <measurement group_id="O2" value="0.35" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.26"/>
                    <measurement group_id="O2" value="2.07" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.50"/>
                    <measurement group_id="O2" value="0.85" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.42"/>
                    <measurement group_id="O2" value="1.88" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" spread="0.13"/>
                    <measurement group_id="O2" value="5.05" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="0.12"/>
                    <measurement group_id="O2" value="4.76" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 1</title>
        <description>Blood samples were collected for fluorescence-activated cell sorting [FACS] analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, Bone-marrow cells (B cells) and natural killer (NK) cells were analyzed using fluorescent-labeled antibodies against clusters of differentiation (CD) markers.</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 1</title>
          <description>Blood samples were collected for fluorescence-activated cell sorting [FACS] analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, Bone-marrow cells (B cells) and natural killer (NK) cells were analyzed using fluorescent-labeled antibodies against clusters of differentiation (CD) markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells per microliter (cells/mcL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.09" spread="134.72"/>
                    <measurement group_id="O2" value="389.17" spread="190.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells (CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1516.27" spread="567.38"/>
                    <measurement group_id="O2" value="1579.00" spread="628.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.73" spread="205.74"/>
                    <measurement group_id="O2" value="376.67" spread="189.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1114.82" spread="415.59"/>
                    <measurement group_id="O2" value="1199.17" spread="496.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.45" spread="134.62"/>
                    <measurement group_id="O2" value="190.67" spread="121.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.27" spread="11.23"/>
                    <measurement group_id="O2" value="8.83" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.64" spread="113.99"/>
                    <measurement group_id="O2" value="273.67" spread="178.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.55" spread="7.62"/>
                    <measurement group_id="O2" value="81.50" spread="168.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.45" spread="12.36"/>
                    <measurement group_id="O2" value="25.00" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="627.45" spread="306.86"/>
                    <measurement group_id="O2" value="673.33" spread="291.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.09" spread="138.98"/>
                    <measurement group_id="O2" value="93.92" spread="97.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.09" spread="245.67"/>
                    <measurement group_id="O2" value="420.92" spread="294.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Differentiated(Diff) EffectorCD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.82" spread="83.60"/>
                    <measurement group_id="O2" value="10.25" spread="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.73" spread="102.47"/>
                    <measurement group_id="O2" value="136.58" spread="77.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.55" spread="29.88"/>
                    <measurement group_id="O2" value="68.25" spread="88.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.91" spread="81.86"/>
                    <measurement group_id="O2" value="113.08" spread="50.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.36" spread="140.97"/>
                    <measurement group_id="O2" value="58.83" spread="52.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.91" spread="34.76"/>
                    <measurement group_id="O2" value="81.92" spread="42.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.27" spread="3.85"/>
                    <measurement group_id="O2" value="7.00" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.09" spread="124.61"/>
                    <measurement group_id="O2" value="143.83" spread="103.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.82" spread="61.05"/>
                    <measurement group_id="O2" value="39.58" spread="27.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.73" spread="132.17"/>
                    <measurement group_id="O2" value="183.42" spread="118.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 1</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>1 Hour Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 1</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.07" spread="128.57"/>
                    <measurement group_id="O2" value="312.69" spread="216.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells (CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1533.53" spread="631.42"/>
                    <measurement group_id="O2" value="1596.54" spread="754.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.07" spread="229.21"/>
                    <measurement group_id="O2" value="372.38" spread="157.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1102.60" spread="450.53"/>
                    <measurement group_id="O2" value="1208.08" spread="651.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.87" spread="182.11"/>
                    <measurement group_id="O2" value="179.15" spread="107.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" spread="9.63"/>
                    <measurement group_id="O2" value="8.92" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.60" spread="111.95"/>
                    <measurement group_id="O2" value="222.75" spread="185.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.20" spread="6.65"/>
                    <measurement group_id="O2" value="78.17" spread="151.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.07" spread="8.04"/>
                    <measurement group_id="O2" value="25.75" spread="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640.07" spread="314.78"/>
                    <measurement group_id="O2" value="706.42" spread="360.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.07" spread="127.98"/>
                    <measurement group_id="O2" value="61.83" spread="45.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.47" spread="197.32"/>
                    <measurement group_id="O2" value="459.75" spread="382.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.93" spread="87.65"/>
                    <measurement group_id="O2" value="4.50" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.40" spread="102.91"/>
                    <measurement group_id="O2" value="141.75" spread="87.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.00" spread="37.44"/>
                    <measurement group_id="O2" value="46.58" spread="64.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.20" spread="50.74"/>
                    <measurement group_id="O2" value="137.33" spread="69.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.53" spread="168.92"/>
                    <measurement group_id="O2" value="39.58" spread="36.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.13" spread="39.65"/>
                    <measurement group_id="O2" value="91.92" spread="55.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="4.75"/>
                    <measurement group_id="O2" value="7.23" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358.33" spread="171.65"/>
                    <measurement group_id="O2" value="136.92" spread="97.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.40" spread="44.65"/>
                    <measurement group_id="O2" value="34.77" spread="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.60" spread="180.18"/>
                    <measurement group_id="O2" value="171.62" spread="104.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 1</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>4 Hours Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 1</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.79" spread="154.52"/>
                    <measurement group_id="O2" value="380.33" spread="220.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells (CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1841.07" spread="880.14"/>
                    <measurement group_id="O2" value="1710.42" spread="959.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505.64" spread="298.97"/>
                    <measurement group_id="O2" value="393.00" spread="205.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1338.79" spread="633.15"/>
                    <measurement group_id="O2" value="1312.92" spread="834.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.50" spread="207.39"/>
                    <measurement group_id="O2" value="201.83" spread="192.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" spread="10.41"/>
                    <measurement group_id="O2" value="10.92" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.50" spread="129.90"/>
                    <measurement group_id="O2" value="265.00" spread="209.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.86" spread="12.60"/>
                    <measurement group_id="O2" value="74.83" spread="129.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.07" spread="10.98"/>
                    <measurement group_id="O2" value="29.17" spread="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785.43" spread="388.64"/>
                    <measurement group_id="O2" value="720.50" spread="383.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.71" spread="165.49"/>
                    <measurement group_id="O2" value="93.42" spread="129.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.43" spread="307.49"/>
                    <measurement group_id="O2" value="488.75" spread="499.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.57" spread="103.39"/>
                    <measurement group_id="O2" value="10.42" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.21" spread="119.89"/>
                    <measurement group_id="O2" value="140.42" spread="90.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.07" spread="52.87"/>
                    <measurement group_id="O2" value="61.33" spread="104.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.71" spread="54.79"/>
                    <measurement group_id="O2" value="142.42" spread="69.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.43" spread="201.13"/>
                    <measurement group_id="O2" value="48.67" spread="58.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.36" spread="42.89"/>
                    <measurement group_id="O2" value="97.83" spread="78.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.21" spread="6.05"/>
                    <measurement group_id="O2" value="7.17" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364.57" spread="191.50"/>
                    <measurement group_id="O2" value="157.17" spread="158.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.57" spread="48.32"/>
                    <measurement group_id="O2" value="37.33" spread="37.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.00" spread="204.21"/>
                    <measurement group_id="O2" value="194.50" spread="191.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 10</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 10</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.50" spread="144.94"/>
                    <measurement group_id="O2" value="310.92" spread="154.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells (CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1732.29" spread="581.98"/>
                    <measurement group_id="O2" value="1477.08" spread="696.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.64" spread="169.81"/>
                    <measurement group_id="O2" value="384.15" spread="216.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1314.64" spread="475.64"/>
                    <measurement group_id="O2" value="1084.62" spread="547.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.79" spread="177.98"/>
                    <measurement group_id="O2" value="205.38" spread="138.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.21" spread="9.96"/>
                    <measurement group_id="O2" value="8.85" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.57" spread="121.71"/>
                    <measurement group_id="O2" value="211.38" spread="133.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.29" spread="20.28"/>
                    <measurement group_id="O2" value="69.23" spread="135.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.50" spread="14.53"/>
                    <measurement group_id="O2" value="21.31" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696.21" spread="294.16"/>
                    <measurement group_id="O2" value="603.54" spread="300.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.86" spread="139.79"/>
                    <measurement group_id="O2" value="78.92" spread="102.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453.86" spread="314.82"/>
                    <measurement group_id="O2" value="393.08" spread="296.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.43" spread="52.47"/>
                    <measurement group_id="O2" value="9.31" spread="18.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.71" spread="95.74"/>
                    <measurement group_id="O2" value="132.46" spread="76.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.57" spread="27.11"/>
                    <measurement group_id="O2" value="69.38" spread="104.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.93" spread="66.75"/>
                    <measurement group_id="O2" value="122.54" spread="91.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.50" spread="114.14"/>
                    <measurement group_id="O2" value="59.77" spread="70.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.64" spread="57.44"/>
                    <measurement group_id="O2" value="79.69" spread="43.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="2.37"/>
                    <measurement group_id="O2" value="8.23" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.50" spread="162.82"/>
                    <measurement group_id="O2" value="149.54" spread="115.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.29" spread="52.45"/>
                    <measurement group_id="O2" value="47.46" spread="35.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.64" spread="176.82"/>
                    <measurement group_id="O2" value="196.92" spread="136.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 28</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 28</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.62" spread="208.61"/>
                    <measurement group_id="O2" value="392.25" spread="235.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells(CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1730.38" spread="730.18"/>
                    <measurement group_id="O2" value="1451.92" spread="622.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.85" spread="143.45"/>
                    <measurement group_id="O2" value="346.58" spread="206.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1352.46" spread="618.78"/>
                    <measurement group_id="O2" value="1102.08" spread="454.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.92" spread="103.73"/>
                    <measurement group_id="O2" value="180.33" spread="123.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.85" spread="8.99"/>
                    <measurement group_id="O2" value="11.25" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.77" spread="177.06"/>
                    <measurement group_id="O2" value="280.50" spread="212.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.31" spread="36.38"/>
                    <measurement group_id="O2" value="73.75" spread="159.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.69" spread="18.14"/>
                    <measurement group_id="O2" value="26.50" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="736.00" spread="272.68"/>
                    <measurement group_id="O2" value="623.67" spread="259.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.54" spread="91.20"/>
                    <measurement group_id="O2" value="90.00" spread="98.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475.23" spread="421.51"/>
                    <measurement group_id="O2" value="378.50" spread="193.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.69" spread="28.46"/>
                    <measurement group_id="O2" value="9.50" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.69" spread="65.03"/>
                    <measurement group_id="O2" value="120.50" spread="68.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.92" spread="25.69"/>
                    <measurement group_id="O2" value="55.50" spread="67.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.38" spread="85.53"/>
                    <measurement group_id="O2" value="121.75" spread="86.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.46" spread="81.53"/>
                    <measurement group_id="O2" value="49.00" spread="61.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.38" spread="54.71"/>
                    <measurement group_id="O2" value="75.08" spread="43.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="2.03"/>
                    <measurement group_id="O2" value="7.17" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.15" spread="78.63"/>
                    <measurement group_id="O2" value="134.25" spread="103.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.77" spread="51.21"/>
                    <measurement group_id="O2" value="38.83" spread="35.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.77" spread="103.02"/>
                    <measurement group_id="O2" value="173.17" spread="119.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 28</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 28</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.21" spread="159.97"/>
                    <measurement group_id="O2" value="329.00" spread="202.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells(CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1705.57" spread="621.55"/>
                    <measurement group_id="O2" value="1630.64" spread="816.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.71" spread="158.79"/>
                    <measurement group_id="O2" value="482.07" spread="388.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1281.00" spread="491.92"/>
                    <measurement group_id="O2" value="1145.50" spread="522.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.43" spread="112.95"/>
                    <measurement group_id="O2" value="339.50" spread="426.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.43" spread="7.84"/>
                    <measurement group_id="O2" value="9.14" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.57" spread="140.28"/>
                    <measurement group_id="O2" value="233.86" spread="171.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.43" spread="20.14"/>
                    <measurement group_id="O2" value="63.00" spread="141.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.57" spread="15.27"/>
                    <measurement group_id="O2" value="23.07" spread="17.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="723.43" spread="253.15"/>
                    <measurement group_id="O2" value="614.50" spread="219.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.21" spread="99.96"/>
                    <measurement group_id="O2" value="143.14" spread="237.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.93" spread="321.41"/>
                    <measurement group_id="O2" value="370.43" spread="199.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.07" spread="31.32"/>
                    <measurement group_id="O2" value="17.43" spread="36.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.50" spread="82.12"/>
                    <measurement group_id="O2" value="128.14" spread="70.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.07" spread="23.82"/>
                    <measurement group_id="O2" value="114.79" spread="187.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.29" spread="83.65"/>
                    <measurement group_id="O2" value="140.07" spread="101.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.21" spread="109.27"/>
                    <measurement group_id="O2" value="98.93" spread="154.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.50" spread="51.93"/>
                    <measurement group_id="O2" value="78.64" spread="41.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="2.43"/>
                    <measurement group_id="O2" value="8.14" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.43" spread="111.98"/>
                    <measurement group_id="O2" value="284.14" spread="394.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.29" spread="25.38"/>
                    <measurement group_id="O2" value="46.93" spread="52.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.64" spread="112.88"/>
                    <measurement group_id="O2" value="331.14" spread="422.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 28</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 28</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.45" spread="194.70"/>
                    <measurement group_id="O2" value="347.67" spread="233.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells(CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1483.00" spread="495.98"/>
                    <measurement group_id="O2" value="1445.83" spread="712.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.27" spread="111.71"/>
                    <measurement group_id="O2" value="346.00" spread="209.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1122.91" spread="419.02"/>
                    <measurement group_id="O2" value="1095.00" spread="565.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.36" spread="59.25"/>
                    <measurement group_id="O2" value="200.75" spread="191.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.73" spread="8.33"/>
                    <measurement group_id="O2" value="10.33" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.91" spread="156.81"/>
                    <measurement group_id="O2" value="247.17" spread="207.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.73" spread="38.69"/>
                    <measurement group_id="O2" value="67.17" spread="129.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.91" spread="17.27"/>
                    <measurement group_id="O2" value="23.17" spread="19.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675.55" spread="270.78"/>
                    <measurement group_id="O2" value="631.50" spread="260.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.09" spread="69.34"/>
                    <measurement group_id="O2" value="85.92" spread="134.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.00" spread="237.45"/>
                    <measurement group_id="O2" value="369.50" spread="314.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.91" spread="30.27"/>
                    <measurement group_id="O2" value="8.17" spread="20.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.09" spread="78.61"/>
                    <measurement group_id="O2" value="112.83" spread="60.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.09" spread="27.50"/>
                    <measurement group_id="O2" value="60.17" spread="91.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.00" spread="90.18"/>
                    <measurement group_id="O2" value="133.17" spread="98.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.91" spread="58.79"/>
                    <measurement group_id="O2" value="40.00" spread="75.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.09" spread="33.05"/>
                    <measurement group_id="O2" value="65.36" spread="36.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="2.42"/>
                    <measurement group_id="O2" value="6.83" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.55" spread="49.57"/>
                    <measurement group_id="O2" value="163.50" spread="158.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.36" spread="25.74"/>
                    <measurement group_id="O2" value="30.50" spread="35.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.64" spread="58.53"/>
                    <measurement group_id="O2" value="193.92" spread="188.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at 8 Hours Post-dose on Day 28</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at 8 Hours Post-dose on Day 28</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382.33" spread="204.55"/>
                    <measurement group_id="O2" value="318.27" spread="253.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells(CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1557.58" spread="601.36"/>
                    <measurement group_id="O2" value="1616.00" spread="934.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.33" spread="135.33"/>
                    <measurement group_id="O2" value="420.18" spread="226.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1203.67" spread="491.02"/>
                    <measurement group_id="O2" value="1186.73" spread="788.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.58" spread="82.07"/>
                    <measurement group_id="O2" value="217.91" spread="148.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" spread="7.10"/>
                    <measurement group_id="O2" value="7.30" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.33" spread="165.84"/>
                    <measurement group_id="O2" value="243.10" spread="220.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.50" spread="38.57"/>
                    <measurement group_id="O2" value="76.60" spread="142.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.00" spread="20.82"/>
                    <measurement group_id="O2" value="22.70" spread="19.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726.75" spread="293.12"/>
                    <measurement group_id="O2" value="725.00" spread="424.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.17" spread="87.92"/>
                    <measurement group_id="O2" value="85.64" spread="127.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.17" spread="270.26"/>
                    <measurement group_id="O2" value="367.73" spread="378.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.83" spread="21.41"/>
                    <measurement group_id="O2" value="8.27" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.92" spread="51.47"/>
                    <measurement group_id="O2" value="149.27" spread="86.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.33" spread="25.27"/>
                    <measurement group_id="O2" value="85.09" spread="110.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.25" spread="95.54"/>
                    <measurement group_id="O2" value="133.64" spread="111.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.08" spread="56.47"/>
                    <measurement group_id="O2" value="52.27" spread="72.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.00" spread="53.92"/>
                    <measurement group_id="O2" value="89.50" spread="72.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="1.80"/>
                    <measurement group_id="O2" value="7.27" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.18" spread="59.33"/>
                    <measurement group_id="O2" value="164.36" spread="125.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.91" spread="29.36"/>
                    <measurement group_id="O2" value="46.27" spread="38.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.91" spread="74.78"/>
                    <measurement group_id="O2" value="210.64" spread="145.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts at 24 Hours Post-dose on Day 28</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts at 24 Hours Post-dose on Day 28</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.00" spread="167.25"/>
                    <measurement group_id="O2" value="300.92" spread="191.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells(CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1044.08" spread="505.60"/>
                    <measurement group_id="O2" value="1619.33" spread="913.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3 CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.92" spread="113.32"/>
                    <measurement group_id="O2" value="382.75" spread="200.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="799.50" spread="408.07"/>
                    <measurement group_id="O2" value="1223.17" spread="779.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.92" spread="52.30"/>
                    <measurement group_id="O2" value="196.67" spread="152.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="4.20"/>
                    <measurement group_id="O2" value="9.75" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.83" spread="146.07"/>
                    <measurement group_id="O2" value="245.33" spread="173.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.58" spread="18.78"/>
                    <measurement group_id="O2" value="24.08" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.83" spread="11.10"/>
                    <measurement group_id="O2" value="21.75" spread="16.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.92" spread="186.89"/>
                    <measurement group_id="O2" value="626.00" spread="339.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.58" spread="41.84"/>
                    <measurement group_id="O2" value="79.50" spread="119.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.17" spread="287.44"/>
                    <measurement group_id="O2" value="508.83" spread="483.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="18.39"/>
                    <measurement group_id="O2" value="9.00" spread="18.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.50" spread="72.10"/>
                    <measurement group_id="O2" value="133.33" spread="83.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.75" spread="8.58"/>
                    <measurement group_id="O2" value="59.17" spread="93.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.25" spread="62.57"/>
                    <measurement group_id="O2" value="142.08" spread="131.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.42" spread="55.68"/>
                    <measurement group_id="O2" value="48.17" spread="60.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.67" spread="41.32"/>
                    <measurement group_id="O2" value="92.58" spread="59.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.11"/>
                    <measurement group_id="O2" value="8.50" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.42" spread="47.76"/>
                    <measurement group_id="O2" value="158.17" spread="137.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.50" spread="12.72"/>
                    <measurement group_id="O2" value="30.08" spread="26.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.08" spread="51.61"/>
                    <measurement group_id="O2" value="187.92" spread="149.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood T, B and NK Lymphocyte Counts and Possible Subsets at Pre-dose on Day 35 or Early Termination</title>
        <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood T, B and NK Lymphocyte Counts and Possible Subsets at Pre-dose on Day 35 or Early Termination</title>
          <description>Blood samples were collected for FACS analysis of lymphocyte subsets. Lymphocyte subset counts of T cells, B cells and NK cells were analyzed using fluorescent-labeled antibodies against CD markers.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B Cells (CD19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.86" spread="95.29"/>
                    <measurement group_id="O2" value="344.17" spread="211.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T Cells (CD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1044.07" spread="529.37"/>
                    <measurement group_id="O2" value="1411.75" spread="474.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T Cells (CD3+CD8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.64" spread="190.57"/>
                    <measurement group_id="O2" value="364.92" spread="202.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells (CD3 CD4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="781.57" spread="350.40"/>
                    <measurement group_id="O2" value="1046.00" spread="328.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK Cells (CD16 CD56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.21" spread="116.20"/>
                    <measurement group_id="O2" value="179.67" spread="142.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immature B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="3.59"/>
                    <measurement group_id="O2" value="11.17" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.43" spread="80.37"/>
                    <measurement group_id="O2" value="252.92" spread="206.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.50" spread="8.72"/>
                    <measurement group_id="O2" value="57.58" spread="102.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory B Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.36" spread="12.73"/>
                    <measurement group_id="O2" value="22.50" spread="13.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.93" spread="167.72"/>
                    <measurement group_id="O2" value="605.00" spread="222.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.29" spread="51.24"/>
                    <measurement group_id="O2" value="97.25" spread="103.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.36" spread="244.79"/>
                    <measurement group_id="O2" value="333.83" spread="132.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector CD4 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" spread="24.88"/>
                    <measurement group_id="O2" value="9.75" spread="16.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.71" spread="58.46"/>
                    <measurement group_id="O2" value="109.42" spread="49.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.93" spread="13.74"/>
                    <measurement group_id="O2" value="70.58" spread="99.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naive CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.79" spread="126.51"/>
                    <measurement group_id="O2" value="133.75" spread="97.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminally Diff Effector Memory CD8 Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.07" spread="67.10"/>
                    <measurement group_id="O2" value="51.08" spread="61.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.64" spread="40.58"/>
                    <measurement group_id="O2" value="73.50" spread="39.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Bright NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="2.60"/>
                    <measurement group_id="O2" value="6.33" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim NK-Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.00" spread="89.92"/>
                    <measurement group_id="O2" value="141.17" spread="130.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.23" spread="72.59"/>
                    <measurement group_id="O2" value="32.25" spread="19.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56 Dim Null NK-Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.15" spread="115.88"/>
                    <measurement group_id="O2" value="173.25" spread="141.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 1</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific Enzyme-Linked Immunosorbent Assay [ELISA] method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples).</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 1</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific Enzyme-Linked Immunosorbent Assay [ELISA] method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples).</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.31" spread="32.24"/>
                    <measurement group_id="O2" value="24.52" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.54" spread="8.23"/>
                    <measurement group_id="O2" value="18.54" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.40" spread="42.59"/>
                    <measurement group_id="O2" value="98.11" spread="37.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 1</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>1 Hour Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 1</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.30" spread="32.40"/>
                    <measurement group_id="O2" value="22.42" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.90" spread="8.12"/>
                    <measurement group_id="O2" value="18.01" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.10" spread="40.23"/>
                    <measurement group_id="O2" value="94.37" spread="39.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 1</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>4 Hours Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 1</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.98" spread="30.72"/>
                    <measurement group_id="O2" value="22.09" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.17" spread="7.30"/>
                    <measurement group_id="O2" value="19.01" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.82" spread="36.77"/>
                    <measurement group_id="O2" value="95.23" spread="38.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 10</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 10</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.10" spread="26.89"/>
                    <measurement group_id="O2" value="21.05" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.35" spread="8.87"/>
                    <measurement group_id="O2" value="18.60" spread="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.13" spread="29.16"/>
                    <measurement group_id="O2" value="91.12" spread="34.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 28</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 28</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.18" spread="22.33"/>
                    <measurement group_id="O2" value="19.26" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.05" spread="9.28"/>
                    <measurement group_id="O2" value="16.51" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.23" spread="17.23"/>
                    <measurement group_id="O2" value="79.93" spread="18.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 28</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 28</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.59" spread="19.30"/>
                    <measurement group_id="O2" value="18.86" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.45" spread="9.65"/>
                    <measurement group_id="O2" value="17.37" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.60" spread="19.24"/>
                    <measurement group_id="O2" value="86.66" spread="29.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 28</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 28</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.71" spread="17.65"/>
                    <measurement group_id="O2" value="16.67" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.09" spread="8.26"/>
                    <measurement group_id="O2" value="15.45" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.52" spread="24.92"/>
                    <measurement group_id="O2" value="86.56" spread="33.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 8 Hours Post-dose on Day 28</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 8 Hours Post-dose on Day 28</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.94" spread="14.38"/>
                    <measurement group_id="O2" value="16.68" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.93" spread="6.37"/>
                    <measurement group_id="O2" value="16.67" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.32" spread="21.32"/>
                    <measurement group_id="O2" value="89.84" spread="33.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 24 Hours Post-dose on Day 28</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 24 Hours Post-dose on Day 28</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.48" spread="20.82"/>
                    <measurement group_id="O2" value="26.20" spread="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.96" spread="9.45"/>
                    <measurement group_id="O2" value="17.49" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.60" spread="22.28"/>
                    <measurement group_id="O2" value="95.51" spread="28.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 35 or Early Termination</title>
        <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 35 or Early Termination</title>
          <description>Blood/serum samples were analyzed for MMP3, osteocalcin and osteopontin concentrations using a validated analytical assay sensitive and specific ELISA method for MMP3 and osteopontin in serum samples; specific electrochemiluminescence method for osteocalcin in blood samples.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.98" spread="21.36"/>
                    <measurement group_id="O2" value="28.72" spread="24.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.79" spread="9.38"/>
                    <measurement group_id="O2" value="16.60" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteopontin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.93" spread="29.73"/>
                    <measurement group_id="O2" value="86.48" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 1</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 1</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.40" spread="17.44"/>
                    <measurement group_id="O2" value="33.32" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 1</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>1 Hour Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 1</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.89" spread="13.44"/>
                    <measurement group_id="O2" value="31.48" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 1</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>4 Hours Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 1</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.97" spread="13.31"/>
                    <measurement group_id="O2" value="33.35" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 10</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 10</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.93" spread="11.76"/>
                    <measurement group_id="O2" value="31.48" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 28</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 28</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.46" spread="12.64"/>
                    <measurement group_id="O2" value="33.39" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 28</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 28</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.97" spread="14.05"/>
                    <measurement group_id="O2" value="33.93" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 28</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 28</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.70" spread="13.25"/>
                    <measurement group_id="O2" value="36.65" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at 8 Hours Post-dose on Day 28</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at 8 Hours Post-dose on Day 28</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.76" spread="15.90"/>
                    <measurement group_id="O2" value="37.82" spread="18.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at 24 Hours Post-dose on Day 28</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at 24 Hours Post-dose on Day 28</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.91" spread="19.94"/>
                    <measurement group_id="O2" value="36.08" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 35 or Early Termination</title>
        <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Level at Pre-dose on Day 35 or Early Termination</title>
          <description>Plasma samples were analyzed for PTH concentrations using a validated, sensitive and specific electrochemiluminescence method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.30" spread="14.86"/>
                    <measurement group_id="O2" value="34.59" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at Pre-dose on Day 1</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at Pre-dose on Day 1</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>picomole per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="2.04"/>
                    <measurement group_id="O2" value="6.21" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 1</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>1 Hour Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 1</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="1.99"/>
                    <measurement group_id="O2" value="5.72" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 1</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>4 Hours Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 1</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>picomole per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="1.53"/>
                    <measurement group_id="O2" value="5.35" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at Pre-dose on Day 10</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at Pre-dose on Day 10</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="1.88"/>
                    <measurement group_id="O2" value="5.82" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at Pre-dose on Day 28</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at Pre-dose on Day 28</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="1.79"/>
                    <measurement group_id="O2" value="5.64" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 28</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 28</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" spread="1.86"/>
                    <measurement group_id="O2" value="5.56" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 28</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 28</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="1.55"/>
                    <measurement group_id="O2" value="5.69" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at 8 Hours Post-dose on Day 28</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at 8 Hours Post-dose on Day 28</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="1.28"/>
                    <measurement group_id="O2" value="5.64" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin (OPG) Level at 24 Hours Post-dose on Day 28</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin (OPG) Level at 24 Hours Post-dose on Day 28</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="2.74"/>
                    <measurement group_id="O2" value="6.20" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Osteoprotegerin(OPG) Level at Pre-dose on Day 35 or Early Termination</title>
        <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteoprotegerin(OPG) Level at Pre-dose on Day 35 or Early Termination</title>
          <description>Blood samples were analyzed for OPG concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="1.70"/>
                    <measurement group_id="O2" value="5.65" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Level of Matrix Metallopeptidase (MMP13)</title>
        <time_frame>Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28</time_frame>
        <population>Analyses of MMP13 was not performed as valid assay for MMP13 was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Level of Matrix Metallopeptidase (MMP13)</title>
          <population>Analyses of MMP13 was not performed as valid assay for MMP13 was not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Level of Interleukin-34 (IL-34) and Interleukin-18 (IL-18)</title>
        <time_frame>Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28</time_frame>
        <population>Analyses of IL-34 and IL-18 were not performed as a valid assay was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Level of Interleukin-34 (IL-34) and Interleukin-18 (IL-18)</title>
          <population>Analyses of IL-34 and IL-18 were not performed as a valid assay was not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 1</title>
        <description>Serum samples were analyzed for SAA concentrations using meso scale discovery (MSD) single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific Electro ChemiLuminescent ImmunoAssay (ECLIA).</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 1</title>
          <description>Serum samples were analyzed for SAA concentrations using meso scale discovery (MSD) single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific Electro ChemiLuminescent ImmunoAssay (ECLIA).</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA (n=14, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26383.03" spread="43196.37"/>
                    <measurement group_id="O2" value="23427.00" spread="43431.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1 (n=14, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.26"/>
                    <measurement group_id="O2" value="0.37" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 1</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>1 Hour Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 1</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25716.93" spread="42986.70"/>
                    <measurement group_id="O2" value="23308.57" spread="41911.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.25"/>
                    <measurement group_id="O2" value="0.32" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 1</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>4 Hours Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 1</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26460.26" spread="46059.64"/>
                    <measurement group_id="O2" value="27297.36" spread="52346.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.12"/>
                    <measurement group_id="O2" value="0.25" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 10</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 10</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5968.89" spread="5509.18"/>
                    <measurement group_id="O2" value="31666.50" spread="92833.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.16"/>
                    <measurement group_id="O2" value="0.35" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 28</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 28</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4094.94" spread="2527.72"/>
                    <measurement group_id="O2" value="14818.88" spread="18346.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.19"/>
                    <measurement group_id="O2" value="0.35" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 28</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 28</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3921.49" spread="2291.33"/>
                    <measurement group_id="O2" value="18976.74" spread="29228.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.16"/>
                    <measurement group_id="O2" value="0.35" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 28</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 28</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4042.21" spread="2974.03"/>
                    <measurement group_id="O2" value="20123.97" spread="31463.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.17"/>
                    <measurement group_id="O2" value="0.20" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 8 Hours Post-dose on Day 28</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 8 Hours Post-dose on Day 28</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA (n=14, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4113.05" spread="2939.86"/>
                    <measurement group_id="O2" value="15403.08" spread="24616.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1 (n=12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.17"/>
                    <measurement group_id="O2" value="0.31" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 24 Hours Post-dose on Day 28</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 24 Hours Post-dose on Day 28</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6643.14" spread="6504.55"/>
                    <measurement group_id="O2" value="14627.28" spread="16685.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.16"/>
                    <measurement group_id="O2" value="0.28" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 35 or Early Termination</title>
        <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 35 or Early Termination</title>
          <description>Serum samples were analyzed for SAA concentrations using MSD single ELISA electrochemiluminescence method and for CTX-1 concentrations using a validated, sensitive and specific ECLIA.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22174.19" spread="25387.79"/>
                    <measurement group_id="O2" value="33853.61" spread="88542.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.15"/>
                    <measurement group_id="O2" value="0.34" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 1</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 1</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545.71" spread="279.48"/>
                    <measurement group_id="O2" value="449.38" spread="163.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 1</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>1 Hour Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 1</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565.43" spread="262.73"/>
                    <measurement group_id="O2" value="479.93" spread="167.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 1</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>4 Hours Post-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 1</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518.29" spread="297.33"/>
                    <measurement group_id="O2" value="477.25" spread="142.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 10</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 10</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.00" spread="265.16"/>
                    <measurement group_id="O2" value="465.00" spread="176.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 28</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 28</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437.73" spread="171.93"/>
                    <measurement group_id="O2" value="617.38" spread="624.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 28</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>1 Hour Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 28</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.00" spread="196.57"/>
                    <measurement group_id="O2" value="501.31" spread="337.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 28</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>4 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 28</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra (n= 13, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.15" spread="147.27"/>
                    <measurement group_id="O2" value="552.85" spread="415.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15 (n=11, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 8 Hours Post-dose on Day 28</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>8 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 8 Hours Post-dose on Day 28</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure. n=participants evaluable for this measure at specified time points for each arm group, respectively.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra (n=12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.08" spread="157.84"/>
                    <measurement group_id="O2" value="414.67" spread="152.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15 (n=12, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 24 Hours Post-dose on Day 28</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 24 Hours Post-dose on Day 28</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500.38" spread="187.55"/>
                    <measurement group_id="O2" value="462.57" spread="175.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.26" spread="0.94"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 35 or Early Termination</title>
        <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 35 or Early Termination</title>
          <description>Serum samples were analyzed for IL-1ra and IL-15 concentrations using a validated, sensitive and specific ELISA method.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="520.87" spread="282.88"/>
                    <measurement group_id="O2" value="486.57" spread="317.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.00"/>
                    <measurement group_id="O2" value="8.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 1</title>
        <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as nanogram per millimoles of creatinine (ng/mmol Cr).</description>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 1</title>
          <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as nanogram per millimoles of creatinine (ng/mmol Cr).</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mmol Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454.74" spread="216.74"/>
                    <measurement group_id="O2" value="345.87" spread="259.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 10</title>
        <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
        <time_frame>Pre-dose on Day 10</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 10</title>
          <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mmol Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.10" spread="208.07"/>
                    <measurement group_id="O2" value="423.76" spread="389.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 28</title>
        <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
        <time_frame>Pre-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 28</title>
          <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>ng/mmol Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320.42" spread="192.31"/>
                    <measurement group_id="O2" value="409.89" spread="338.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at 24 Hours Post-dose on Day 28</title>
        <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
        <time_frame>24 Hours Post-dose on Day 28</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at 24 Hours Post-dose on Day 28</title>
          <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mmol Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.86" spread="159.63"/>
                    <measurement group_id="O2" value="284.87" spread="202.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 35 or Early Termination</title>
        <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
        <time_frame>Pre-dose on Day 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 35 or Early Termination</title>
          <description>Urinary concentration of collagen type II C-telopeptide fragments was measured by competitive ELISA. uCTX-II was measured as ng/mmol Cr.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication. Here, 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ng/mmol Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.55" spread="198.90"/>
                    <measurement group_id="O2" value="340.83" spread="379.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% Response</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Day 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% Response</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
        <description>ACR50 response: &gt;=50% improvement in TJC; &gt;= 50% improvement in SJC; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Day 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
          <description>ACR50 response: &gt;=50% improvement in TJC; &gt;= 50% improvement in SJC; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
        <description>ACR70 response: &gt;=70% improvement in TJC; &gt;= 70% improvement in SJC; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Day 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
          <description>ACR70 response: &gt;=70% improvement in TJC; &gt;= 70% improvement in SJC; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
        <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP) (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6 implied remission.</description>
        <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
          <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP) (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6 implied remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="0.87"/>
                    <measurement group_id="O2" value="5.06" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="0.78"/>
                    <measurement group_id="O2" value="5.22" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="0.97"/>
                    <measurement group_id="O2" value="4.91" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="1.10"/>
                    <measurement group_id="O2" value="4.79" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Day 28 and 35</title>
        <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP (mg/mL). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Day 1 (Baseline), 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Day 28 and 35</title>
          <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP (mg/mL). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="0.97"/>
                    <measurement group_id="O2" value="-0.31" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.96"/>
                    <measurement group_id="O2" value="-0.43" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) &lt;=3.2 and &lt;2.6</title>
        <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP (mg/mL). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) &lt;=3.2 and &lt;2.6</title>
          <description>DAS28-3 (CRP) was calculated from the SJC, TJC using the 28 joints count and the CRP (mg/mL). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7: DAS28-3 (CRP) &lt;=3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day -7: DAS28-3 (CRP) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Baseline): DAS28-3 (CRP) &lt;=3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Baseline): DAS28-3 (CRP) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: DAS28-3 (CRP) &lt;=3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: DAS28-3 (CRP) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination: DAS28-3 (CRP) &lt;=3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination: DAS28-3 (CRP) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</title>
        <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</title>
          <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="0.98"/>
                    <measurement group_id="O2" value="6.17" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="0.98"/>
                    <measurement group_id="O2" value="6.32" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="1.11"/>
                    <measurement group_id="O2" value="6.03" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="1.23"/>
                    <measurement group_id="O2" value="6.00" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Day 28 and 35</title>
        <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR [mm/hour] and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Day 1 (Baseline), 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Day 28 and 35</title>
          <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR [mm/hour] and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="1.02"/>
                    <measurement group_id="O2" value="-0.30" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.91"/>
                    <measurement group_id="O2" value="-0.32" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) &lt;=3.2 and &lt;2.6</title>
        <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR [mm/hour] and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Day -7, 1 (Baseline), 28, 35 or Early Termination</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) &lt;=3.2 and &lt;2.6</title>
          <description>DAS28-4 (ESR) was calculated from the number of SJC, TJC using the 28 joints count, ESR [mm/hour] and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) &lt;= 3.2 implied low disease activity, &gt; 3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of the study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7: DAS28-4 (ESR) =&lt;3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day -7: DAS28-4 (ESR) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Baseline): DAS28-4 (ESR) =&lt;3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Baseline): DAS28-4 (ESR) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: DAS28-4 (ESR) =&lt;3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: DAS28-4 (ESR) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination: DAS28-4 (ESR) =&lt;3.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 or Early Termination: DAS28-4 (ESR) &lt;2.6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA v14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

